Tanager Wealth Management LLP Acquires New Shares in Johnson & Johnson (NYSE:JNJ)

Tanager Wealth Management LLP acquired a new stake in Johnson & Johnson (NYSE:JNJFree Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,502 shares of the company’s stock, valued at approximately $238,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Granite Harbor Advisors Inc. lifted its position in Johnson & Johnson by 5.9% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 6,609 shares of the company’s stock worth $1,029,000 after acquiring an additional 366 shares during the last quarter. Kampmann Melissa S. acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $3,674,000. Tompkins Financial Corp raised its position in shares of Johnson & Johnson by 1.4% during the third quarter. Tompkins Financial Corp now owns 33,823 shares of the company’s stock valued at $5,268,000 after buying an additional 461 shares during the last quarter. Carlson Capital Management increased its stake in Johnson & Johnson by 1.4% in the third quarter. Carlson Capital Management now owns 13,912 shares of the company’s stock valued at $2,167,000 after acquiring an additional 187 shares during the period. Finally, Allen Mooney & Barnes Investment Advisors LLC bought a new stake in Johnson & Johnson in the third quarter valued at about $1,341,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $146.48 on Monday. The firm has a 50-day moving average of $147.94 and a 200-day moving average of $153.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The company has a market cap of $352.53 billion, a PE ratio of 9.13, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.68 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.39%. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective on the stock. Morgan Stanley cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $174.07.

Get Our Latest Research Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.